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Aims We examined the prognostic importance of cardiac troponin I (cTnI) in a cohort of patients enrolled in the
ASCEND-HF study of nesiritide in acute decompensated heart failure (ADHF). Circulating troponins are a prognostic
marker in patients with ADHF. Contemporary assays with greater sensitivity require reassessment of the significance
of troponin elevation in HF.
Methods
and results
Cardiac troponin I was measured in a core laboratory in 808 ADHF patients enrolled in the ASCEND-HF biomarkers
substudy using a sensitive assay (VITROS Trop I ES, Ortho Clinical Diagnostics) with a lower limit of detection of
0.012 ng/mL and a 99th percentile upper reference limit (URL) of 0.034 ng/mL. Patients with clinical evidence of
acute coronary syndrome or troponin .5× the URL were excluded. Multivariable modelling was used to assess
the relationship between log(cTnI) and in-hospital and post-discharge outcomes. Baseline cTnI was undetectable
in 22% and elevated above the 99th percentile URL in 50% of subjects. cTnI levels did not differ based on HF aeti-
ology. After multivariable adjustment, higher cTnI was associated with worsened in-hospital outcomes such as length
of stay (P ¼ 0.01) and worsening HF during the index hospitalization (P ¼ 0.01), but was not associated with wor-
sened post-discharge outcomes at 30 or 180 days. The relationship between cTnI and outcomes was generally
linear and there was no evidence of a threshold effect at any particular level of cTnI.
Conclusion cTnI is elevated above the 99th percentile URL in 50% of ADHF patients and predicts in-hospital outcome, but is not
an independent predictor of long-term outcomes.
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Introduction
Cardiac troponins are sensitive biomarkers of myocardial injury,
and play a fundamental role in the diagnosis and risk stratification
of patients with acute coronary syndromes (ACS). Data from mul-
tiple studies have demonstrated that circulating cardiac troponins
are detectable in patients with heart failure (HF) even in the
absence of clinically apparent myocardial ischaemia, and that
cardiac troponins may be useful prognostic markers in patients
with acute and chronic HF.1 Although the exact mechanisms of
myocardial injury in HF are uncertain, ischaemia, haemodynamic
stress, oxidative stress, inflammation, altered calcium handling,
and impaired renal clearance have all been proposed as mechan-
isms of troponin elevation in HF.1,2
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Recent improvements in the sensitivity of troponin assays have
complicated the interpretation of these biomarkers in HF. The in-
creasing sensitivity of more contemporary assays has resulted in
the detection of circulating troponin in a progressively greater pro-
portion of HF patients, including many patients with troponin levels
greater than the diagnostic myocardial infarction threshold [the
99th percentile upper reference limit (URL)]. This phenomenon
has led to increasing uncertainty about the clinical interpretation
of troponin data from contemporary assays, particularly in patients
with acute decompensated HF (ADHF). A substantial proportion
of ADHF patients have elevations of circulating troponin,3 –5 and
both the symptoms and the aetiology of ADHF may overlap signifi-
cantly with those of ACS. Using a contemporary troponin assay, we
analysed data from a pre-specified biomarker substudy of the
ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in
Decompensated Heart Failure) study in order to assess (i) the
prevalence and clinical correlates of troponin elevation in ADHF;
(ii) the association between troponin elevation and in-hospital and
post-discharge clinical outcomes; (iii) the prognostic implications of
changes in troponin levels during initial ADHF therapy; and (iv)
the relationship between nesiritide treatment and troponin status.
Methods
The methods and primary results of the ASCEND-HF study
(NCT00475852, clinical trials.gov) have been published previously.6,7
Briefly, ASCEND-HF was a multicentre, randomized, double-blind,
placebo-controlled trial of nesiritide compared with placebo in 7141
patients hospitalized with ADHF. Co-primary endpoints were im-
provement in dyspnoea at 6 or 24 h as measured by a 7-point Likert
scale and HF hospitalization or death at 30 days. Patients with clinical
evidence of ACS or baseline troponin level .5× the URL at the local
clinical laboratory were excluded from the trial. A subgroup of patients
from the ASCEND-HF study were enrolled in a biomarker substudy
(n ¼ 808). Blood samples were obtained in serum and EDTA plasma
at baseline, 48–72 h, and 30 days, and were immediately centrifuged
and stored at –808C for subsequent analysis. At a central core labora-
tory blinded to all clinical data, cardiac troponin I (cTnI) was measured
in serum samples using a contemporary ‘guideline-acceptable’8 sensi-
tive assay (VITROS Trop I ES, Ortho Clinical Diagnostics, Raritan,
NJ, USA) with a lower limit of detection of 0.012 ng/mL, a 99th per-
centile URL of 0.034 ng/mL, and a coefficient of variation of 10% at
the 99th percentile URL. N-terminal pro brain natriuretic peptide
(NT-proBNP) was measured on serum samples at the same core la-
boratory using a clinically available assay (VITROS NTproBNP,
Ortho Clinical Diagnostics).
Statistical analysis
Categorical variables were described as counts and percentages, and
continuous variables were summarized as medians (25th, 75th percen-
tiles). Differences in binary variables were calculated using the x2 test.
Continuous and ordinal variables were compared using the Wilcoxon
rank-sum test. Because cTnI was not normally distributed, this variable
was log transformed in all analyses using log base 2, such that reported
hazard ratios (HRs) and odds ratios (ORs) represented the risk asso-
ciated with a doubling of cTnI. All ORs and HRs are reported as point
estimates with 95% confidence intervals (CIs). For the purposes of
analysis, levels below the lower limit of detection (,0.012 ng/mL)
were imputed as 0.006 ng/mL, since this provided the best statistical
fit for the observed distribution of troponin data. We used multivari-
able linear regression to identify clinical predictors of elevated cTnI at
baseline. The association between cTnI and outcomes was determined
using both univariable and multivariable logistic regression analysis or
Cox proportional hazards analysis (for length of stay and 180-day mor-
tality). The clinical endpoints of interest were (i) 30-day mortality; (ii)
the composite of 30-day mortality and rehospitalization for HF; (iii)
180-day mortality; (iv) dyspnoea improvement at 6 and 24 h; (v) wor-
sening HF or death up to day 7; and (vi) length of stay for the index
hospitalization. For multivariable analysis, adjusted models for each
endpoint of interest (‘final adjusted models’) were constructed in the
overall ASCEND-HF population (see Appendix for the final list of cov-
ariates for each endpoint). These covariates were then used to
perform multivariable adjustment in the biomarker substudy subset
reported herein. Models were tested with and without the inclusion
of NT-proBNP. We also examined the interaction between rando-
mized treatment (nesiritide or placebo) and troponin status with
regard to each outcome using an interaction term (treatment ×
cTnI) in the multivariable model for each endpoint.
To evaluate the relationship between change in cTnI during the acute
hospitalization (between baseline and 48–72 h) and subsequent out-
comes, we evaluated both the absolute change in troponin values and
a 20% change in troponin from baseline. Both these analyses excluded
patients with undetectable troponin at baseline. Finally, we examined
the significance of a rise or fall in troponin that crossed the 99th percent-
ile URL, consistent with the universal definition of myocardial infarction.9
Results
Patient population
The biomarker substudy population (n ¼ 808) was broadly similar
to the overall ASCEND-HF population (n ¼ 7141), with the ex-
ception that 85% of patients in the biomarker substudy were en-
rolled in North America (compared with 43% in the main trial).
The median cTnI level was 0.034 ng/mL (0.012, 0.058). Baseline
cTnI was below the lower limit of detection (,0.012 ng/mL) in
22% and elevated above the 99th percentile URL in 50%. The pro-
portion of patients with cTnI levels above the 99th percentile URL
decreased at each time point, but remained substantial (31%) even
at day 30 (Figure 1). Baseline characteristics for the study popula-
tion stratified by cTnI above or below the 99th percentile URL
(which was also the median cTnI level) are shown in Table 1.
Patients with higher cTnI levels had other characteristics associated
with higher risk, including being older, more often male, and having
higher NT-proBNP and worse renal function (P, 0.05 for all).
Notably, cTnI levels did not differ based on whether patients had
HF of ischaemic vs. non-ischaemic aetiology (median cTnI ¼
0.034 ng/mL for ischaemic vs. 0.035 ng/mL for non-ischaemic; P ¼
0.77). Patients with HF and preserved ejection fraction ( ≥ 40%)
had significantly lower cTnI levels (median¼ 0.026 ng/mL) than
those with systolic dysfunction (median¼ 0.037; P ¼ 0.03) (Figure 2).
Correlates of elevated baseline troponin
Variables that were significantly associated with elevated cTnI at
baseline are shown in Table 2. The factor with by far the strongest
association with elevated cTnI was elevated NT-proBNP
(P, 0.0001). Region was also a significant predictor of elevated
cTnI, with patients enrolled in North America or Latin America
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having lower cTnI levels than those enrolled in other regions
(Western Europe, Central Europe, or Asia).
Association of baseline troponin and
outcomes
In-hospital outcomes
For analysis of the relationship between cTnI and dyspnoea re-
sponse, dyspnoea was dichotomized as moderately or markedly
improved (based on the Likert scale) at 6 and 24 hrelative to the
time of randomization. Baseline cTnI was not a significant predictor
of dyspnoea relief at 6 h (adjusted OR 1.04, 95% CI 0.92–1.18) per
doubling of cTnI; P ¼ 0.502), but troponin elevation was modestly
associated with lower odds of dyspnoea relief at 24 h (adjusted OR
0.85, 95% CI 0.72–0.99 per doubling of cTnI; P ¼ 0.035) (Table 3).
Baseline troponin status was a strong predictor of other clinical
outcomes during the index hospitalization. Specifically, increased
baseline cTnI was associated with a higher risk of the endpoint
of death or worsening HF prior to discharge in both univariate
(OR 1.31, 95% CI 1.12–1.54 per doubling of cTnI; P ¼ 0.001)
and multivariable analysis (OR 1.34, 95% CI 1.10–1.62 per doub-
ling of cTnI; P ¼ 0.013) (Figure 3A). Increases in baseline cTnI
were also associated with a higher risk for increased length of
stay in both univariate analysis (HR 0.93, 95% CI 0.89–0.97; P ¼
0.001) and after adjustment for other known predictors (HR
0.95, 95% CI 0.91–0.99; P ¼ 0.013).
Long-term outcomes
Event rates were 3.1% (n ¼ 25) for 30-day mortality, 12.1% (n ¼
98) for the composite of death or rehospitalization at 30 days,
and 11.5% (n ¼ 93) for 180-day mortality. The univariable and
adjusted relationships between baseline cTnI and 30- and
180-day outcomes are shown in Table 3. Higher baseline cTnI
was associated with a higher 30-day mortality rate in univariate
analysis (OR 1.23, 95% CI 1.01–1.50 per doubling of cTnI;
P ¼ 0.035). However, after adjustment for other predictors, cTnI
was no longer associated with 30-day mortality (adjusted OR
1.11, 95% CI 0.89–1.38 per doubling of cTnI; P ¼ 0.37)
(Figure 3B). For the composite endpoint of death or HF rehospita-
lization at 30 days, elevated cTnI was not significantly associated
with outcome in either univariable (OR 1.09, 95% CI 0.97–1.22;
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Table 1 Baseline characteristics stratified by troponin I above or below the 99th percentile upper reference limit
Total (n 5 808) cTnI ≤0.034 ng/L (n 5 404) cTnI >0.034 ng/mL (n 5 404) P-value
Age (years) 67 65 69 0.022
Sex (male, %) 70.1 64.6 75.5 0.0007
Race (White, %) 68.2 68.8 67.6 0.84
Systolic BP (mmHg) 124.0 124.0 124.5 0.52
Heart rate (b.p.m.) 79.0 79.0 79.0 0.82
Atrial fibrillation (%) 41.3 40.6 42.1 0.67
Hypertension (%) 77.7 80.2 75.3 0.091
NT-proBNP (pg/mL) 3700 2980 4554 0.0008
Serum creatinine (mmol/L) 114.9 106.1 123.8 ,0.0001
BUN (mg/dL) 8.6 8.2 9.6 0.0001
Sodium (mmol/L) 139 139 139 0.038
EF (%) 25 30 25 0.052
Time from presentation to randomization (h) 18.1 18.8 17.3 0.094
Ischaemic aetiology (%) 60.6 61.1 60.2 0.77
On beta-blocker (%) 75.5 78.0 73.0 0.10
On ACE inhibitor or ARB (%) 64.2 65.4 63.1 0.51
On aldosterone antagonist (%) 24.6 27.5 21.8 0.060
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; BUN, blood urea nitrogen; cTnI, cardiac troponin I; EF, ejection fraction;
NT-proBNP, N-terminal pro brain natriuretic peptide.
Figure 1 Proportion of patients at each time point with tropo-
nin I values below the lower limit of detection (,0.012 ng/mL),
between the lower limit of detection and the 99th percentile
URL (≥0.012 ng/mL to ≤0.034 ng/mL), and greater than the
99th percentile URL (.0.034 ng/mL). URL, upper reference limit.
Troponin I in acute decompensated heart failure Page 3 of 8
 at European Society of Cardiology on Septem
ber 14, 2012
http://eurjhf.oxfordjournals.org/
D
ow
nloaded from
 
P ¼ 0.15) or multivariable (OR 1.04, 95% CI 0.92—1.18; P ¼ 0.51)
analyses. For 180-day mortality, elevations of baseline cTnI were
associated with higher mortality in univariable analysis (HR 1.25,
95% CI 1.13–1.38 per doubling of cTnI; P, 0.0001), but were
no longer significant after adjustment for other predictors
(adjusted HR 1.11, 95% CI 0.99–1.25 per doubling of cTnI; P ¼
0.086).
Change in troponin status and outcomes
A total of 685 patients had paired samples from both the baseline
and 48–72 h time point available for analysis. Event rates in
patients with paired samples were generally similar to those in
patients without paired samples available (data not shown).
In general, cTnI levels from baseline to the 48–72 h time point
were highly correlated (r ¼ 0.77; P, 0.001). There was no signifi-
cant association between the absolute change in troponin from
baseline to 48–72 h and either 30-day mortality (P ¼ 0.063) or
the composite of 30-day death or heart failure hospitalization
(P ¼ 0.14). When troponin change was dichotomized at a 20% in-
crease, 30-day event rates were higher for those with a troponin
increase (Table 4), and a 20% increase in troponin was a significant
predictor of 30-day death (P ¼ 0.012) but not 30-day death or HF
hospitalization (P ¼ 0.304). Finally, we assessed the clinical signifi-
cance of a rise or fall in troponin that crossed the 99th percentile
URL (consistent with the universal definition for myocardial infarc-
tion). Event rates for 30-day endpoints (death and death or HF
rehospitalization) based on changes in troponin status are shown in
Figure 4. Although crude event rates were numerically highest for
patients with persistently elevated cTnI, there was no clear and con-
sistent relationship between change in troponin category and 30-day
outcome for either mortality or the composite of mortality and
rehospitalization. Notably, patients whose cTnI went from low to
high during the course of treatment (presumably suggestive of
ongoing or worsening myocardial injury) actually had the lowest
event rate for the composite of death or HF hospitalization at 30 days.
When both baseline and 48–72 h log(cTnI) were entered to-
gether into a logistic regression model for 30-day mortality, the
48–72 h cTnI level remained a significant predictor (P ¼ 0.04),
whereas the baseline cTnI level did not (P ¼ 0.81), suggesting
that the most recent value provided the most prognostic informa-
tion. In a similar analysis examining change from baseline to 30- and
180-day outcomes, the 30-day cTnI level remained a significant
predictor (P ¼ 0.0001) whereas baseline cTnI did not (P ¼ 0.434).
Interaction between troponin status and
treatment
Given that ASCEND-HF was a randomized controlled study of
nesiritide, we evaluated the association between treatment assign-
ment (nesiritide or placebo) and troponin status using interaction
terms in the relevant multivariable model for each endpoint. There
was no evidence of a differential effect of nesiritide treatment
based on troponin status for either dyspnoea at 24 h (P ¼ 0.56
for treatment × cTnI interaction) or for the 30-day composite of
death or HF rehospitalization (P ¼ 0.42 for treatment × cTnI
interaction). Additionally, we investigated whether the changes in
cTnI during initial ADHF treatment differed by treatment assign-
ment (nesiritide or placebo). There was no significant difference
between 72 h cTnI (while controlling for baseline troponin)
based on treatment assignment (P ¼ 0.56), suggesting that nesiri-
tide treatment did not affect changes in cTnI over time.
Discussion
The ongoing development of more sensitive assays for troponin
has led to uncertainty about the clinical significance of detectable
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Predictors of higher baseline troponin I levels by linear regression
Variable Coefficient 95% CI F-value P-value
Log(NT-proBNP) 0.212 0.140–0.284 33.38 ,0.0001
Regiona NA 5.21 0.0004
Log(BUN) 0.171 0.015–0.327 4.66 0.0313
Potassium 0.122 0.007–0.237 4.30 0.0385
No diabetes –0.150 –0.294 to –0.022 4.13 0.0424
No atrial fibrillation –0.141 –0.286 to 0.004 3.62 0.0576
BUN, blood urea nitrogen; CI, confidence interval; NT-proBNP, N-terminal pro brain natriuretic peptide.
aNorth America, Latin America, Central Europe, Western Europe, or Asia.
Figure 2 Relationship between heart failure aetiology, ejection
fraction (EF), and baseline cardiac troponin I (cTnI).
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or elevated troponin levels in patients with HF. Specifically,
improvements in analytical sensitivity have transformed circulating
troponin from a biomarker that was only detectable in a minority
of patients to one that is detectable in the vast majority of patients
with HF and elevated (above the 99th percentile URL) in a sub-
stantial minority.
In the current analysis of a substudy from the ASCEND-HF trial,
we found a high prevalence of baseline cTnI levels that were de-
tectable (78%) or elevated above the 99th percentile URL (50%)
using a contemporary sensitive troponin assay. The prevalence of
cTnI elevation in our study was generally higher than in previously
published reports in ADHF, where the prevalence of troponin ele-
vation above the 99th percentile URL has ranged from 6% to
83%.4,5,10– 13 Previous studies of troponin prevalence have been
either small single-centre studies5,14 –16 or pooled data from
large registries such as ADHERE and EFFECT4,11 and have gener-
ally used older assays or pooled clinical data from multiple sites
using a variety of assays. Thus, the current analysis from
ASCEND-HF is the largest study to date reporting troponin data
in ADHF patients using a centralized core laboratory and a con-
temporary sensitive assay. Additionally, our study utilized carefully
adjudicated clinical events using a blinded endpoints committee,
further adding to the validity of our findings.
The ongoing evolution of troponin assays has resulted in assays
of markedly greater sensitivity (at least 10-fold); not surprisingly,
this led to substantial increases in the proportion of HF patients
with detectable (i.e. above the lower limit of detection) and ele-
vated (i.e. above the 99th percentile URL) troponin. Consistent
with this trend, a recent single-centre study by Xue et al. demon-
strated, using an experimental ultrasensitive nanoparticle assay,
that the median troponin value in an ADHF population was
29.5 ng/L (. 4-fold greater than the 99th percentile URL for
that assay) and all ADHF patients studied had detectable tropo-
nin.14 These progressive improvements in analytical sensitivity
have resulted in the commonly used distinction of troponin as
‘positive’ or ‘negative’ becoming increasingly meaningless in the
context of ADHF, where the vast majority of patients have detect-
able troponin using contemporary sensitive assays.
In our analysis, elevations in baseline cTnI were independent
predictors of events during the acute index hospitalization (wor-
sening or persistent HF or death as well as increased length of
stay) and modestly predicted lack of dyspnoea improvement at
24 h. In this analysis, cTnI levels, while predictive of in-hospital out-
comes, were not independent predictors of post-discharge out-
comes at 30 or 180 days after adjustment for other known
predictors. These results are generally consistent with previous
results from ADHERE examining in-hospital events,4 but are in
contrast to previous published studies that have consistently
shown troponin elevation to be an independent predictor of post-
discharge outcomes in ADHF.5,10,11,16–18 The reasons underlying the
difference between our results and previous data in ADHF are specu-
lative. Our study is several fold larger than any previous study (ex-
cluding the two large registry studies), suggesting that limited
statistical power (i.e. type II error) is an unlikely explanation for our
results. Our study included relatively robust adjustment for other
covariates, which may have served to attenuate the prognostic signifi-
cance of troponin in the face of other strong predictors of outcome.
The ASCEND-HF study excluded patients with troponin. 5-fold
the URL, and so the exclusion of patients with very elevated troponin
levels may have limited our ability to detect associations between
troponin and outcomes. Finally, publication bias may contribute to
the lack of other reports in the literature showing no association
between troponin and post-discharge outcomes.
Changes in troponin status during initial treatment for ADHF
have been proposed as potentially important signals in drug devel-
opment.19 Previous studies in both chronic and acute HF have sug-
gested that changes in troponin over time are associated with
greater risk.18,20 In the current analysis, troponin values were rela-
tively stable over the initial 48–72 h of ADHF therapy. Substantial
increases in troponin (. 20%) were associated with risk for 30-day
mortality but not for the composite of death or HF rehospitaliza-
tion. The most recent value available provided the most important
prognostic information in predicting outcomes, consistent with
recent data on the natriuretic peptides.21 Of particular interest
in our analysis were patients whose troponin either rose above
the 99th percentile URL (5%; n ¼ 33) or fell below the 99th
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Baseline troponin I levels and outcomes
Endpoint Unadjusted Adjusteda
ORb or HRb 95% CI x2 P-value ORb or HRb 95% CI x2 P-value
Death at 30 days 1.234 1.014–1.501 4.42 0.035 1.106 0.887–1.379 0.80 0.37
Death/rehospitalization at 30 days 1.090 0.970–1.224 2.08 0.15 1.043 0.919–1.184 0.43 0.51
Death at 180 days 1.246 1.126–1.377 18.3 ,0.0001 1.108 0.985–1.247 2.95 0.086
Improved dyspnoea at 6 h 1.008 0.930–1.093 0.04 0.84 1.037 0.933–1.153 0.45 0.502
Improved dyspnoea at 24 h 0.886 0.788–0.991 4.02 0.045 0.845 0.724–0.988 4.47 0.035
Death or worsening HF prior to discharge 1.310 1.115–1.538 10.8 0.001 1.336 1.101–1.620 8.65 0.013
Length of stayc 0.931 0.894–0.970 11.7 0.001 0.946 0.905–0.988 6.14 0.013
CI, confidence interval; HF, heart failure; HR, hazard ratio; OR, odds ratio.
aAdjusted models using th ecovariates listed in Appendix for each endpoint.
bPer doubling of cardiac troponin I.
cFor length of stay, a numerically lower hazard ratio equates to high risk for increased length of stay.
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Table 4 Change in troponin from baseline to 48–72 h and 30-day outcomes
Endpoint, % (n/N) Event rates based on 20% increase in troponin
No 20% increase 20% increase P-value
30-day death 2.3% (10/441) 7.7% (7/91) 0.012
30-day death/HF rehospitalization 12.5% (55/441) 16.5% (15/91) 0.304
Endpoint Absolute change in troponin and 30-day endpoints
OR 95% CI Wald x2 P-value
30-day death 0.762 0.572–1.015 3.46 0.063
30-day death/HF rehospitalization 0.856 0.696–1.054 2.14 0.144
CI, confidence interval; HF, heart failure; OR, odds ratio.
Figure 3 Continuous relationship between baseline troponin I and (A) in-hospital worsening heart failure or death to day 7, and (B) 30-day mortality.
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percentile URL (16%; n ¼ 107) between baseline and 48–72 h
measurements. Given that the clinical presentation of acute HF
and ACS substantially overlaps, this subgroup of patients satisfies
many of the diagnostic criteria for acute myocardial infarction
using the current universal definition, which requires a rise and/
or fall in cardiac troponin with at least one value above the 99th
percentile URL in the setting of appropriate clinical symptoms.9
Absolute changes in troponin in these groups were modest, with
a median rise of 0.031 ng/mL in the low–high group and a
median fall of 0.025 ng/mL in the high–low group. Despite these
changes in troponin status during acute therapy, there was no
clear or consistent pattern in event rates based on these categor-
ies, as shown in Figure 4. These data call into question the clinical
significance of modest changes in troponin in the context of acute
HF, a finding that may have potential implications for the use of
troponin monitoring to identify cardiotoxicity in drug develop-
ment.22 Larger increases in troponin during acute treatment may
have prognostic implications for post-discharge events.
Given the importance of the 99th percentile URL in current
guidelines for diagnosing myocardial infarction,9 we evaluated
whether there was any evidence for a threshold effect (a change
in the slope of the risk curve) at this level of cTnI values. Graphical
evaluation of the continuous relationship between cTnI and risk of
in-hospital worsening HF/death to day 7 (Figure 3A) or 30-day mor-
tality (Figure 3B) did not suggest a threshold effect at any particular
level of cTnI. Combined with our data showing little significance of
the changes in troponin categories based on troponin levels above
or below this threshold, the data from ASCEND-HF generally raise
questions regarding the relevance of the 99th percentile URL in
the evaluation and management of patients with ADHF.
Important limitations of our study include the selection bias in-
herent in clinical trial populations, as well as the fact that patients
with clinical evidence of ACS and elevations of troponin .5× the
URL were excluded from the ASCEND-HF trial. If anything, these
exclusion criteria would bias our data towards an underestimate of
the prevalence of elevated troponin levels in less selected ADHF
populations. However, this limitation may also have led us to
underestimate the prognostic importance of troponin elevations
in ADHF patients with a broader range of troponin values. The ma-
jority of our substudy population was from North America, poten-
tially limiting the generalizability of our results. Patients in
ASCEND-HF could be randomized as long as 24 h after initiation
of intravenous therapy, and thus baseline cTnI levels in our study
may have differed from those that would have been obtained at
initial presentation. The relatively long time window between base-
line and follow-up sampling (48–72 h) may have obscured shorter
term changes in troponin levels. Although our study was relatively
large compared with other similar studies in the literature, the total
number of events was still small, which may have limited our stat-
istical power. Finally, our study was a retrospective analysis of data
from a clinical trial, and thus cannot establish cause and effect.
The ongoing development of troponin assays of progressively
greater sensitivity necessitates a change in thinking about troponin
as a dichotomous variable (with associated ‘cut-off points’) to a
continuous prognostic variable (similar to the natriuretic peptides),
a change that has resulted in substantial uncertainty in the clinical
community.23 In this analysis of a large clinical trial population, cTnI
levels were associated with in-hospital outcomes but not post-
discharge outcomes in a large cohort of patients with ADHF.
Given that these results differ from those of other recent ana-
lyses,24,25 they will require confirmation in other data sets.
Further research with contemporary assays is needed to define
the appropriate role of troponin as a biomarker in the clinical
care of patients with HF.
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Appendix
Final covariates for multivariable adjustment for each endpoint were
based on multivariable modelling from the overall ASCEND-HF
cohort, and then applied to models for each endpoint in the troponin
subset. Final adjustment covariates for each endpoint are shown
below.
Death at 30 days
Age, log(BUN), serum sodium, hypotension (baseline), dyspnoea at
rest (baseline).
Figure 4 Thirty-day event rates by change in troponin category
from baseline to 48–72 h. High and low troponin categories
based on level above or below the 99th percentile upper refer-
ence limit.
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Death or HF rehospitalization at 30 days
Hypotension (baseline), serum sodium, age, log(BUN), history of
cerebrovascular disease (baseline), log(creatinine), history of de-
pression, dyspnoea at rest (baseline), elevated jugular venous pres-
sure (JVP), history of chronic respiratory disease.
Length of stay
Hypotension (baseline), serum sodium, age, log(BUN), history of
cerebrovascular disease (baseline), log(creatinine), history of de-
pression, dyspnoea at rest (baseline), elevated JVP, history of
chronic respiratory disease.
Dyspnoea at 6 h
Age, serum sodium, respiratory rate (baseline), congestion on
chest X-ray, race, hypotension (baseline), haemoglobin,
log(BUN), New York Heart Association (NYHA) class prior to
decompensation.
Dyspnoea at 24 h
Age, serum sodium, respiratory rate (baseline), congestion on
chest X-ray, race, hypotension (baseline), haemoglobin, NYHA
class prior to decompensation.
Death at 180 days
Age, log(BUN), serum sodium, hypotension (baseline), dyspnoea at
rest (baseline).
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